نتایج جستجو برای: triple negative

تعداد نتایج: 572352  

2016
Mustapha Akanji Ajani Ayodeji Akeem Salami Olutosin Alaba Awolude Abideen Olayiwola Oluwasola Saad Aliyu Ahmed Akinwumi Komolafe

Background: Triple negative epithelial ovarian cancer (TNEOC)  refers to ovarian carcinomas that do not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor- type 2 (HER-2/neu).  The aim of this study is to determine the pattern of triple negative epithelial ovarian cancer in indigenous African women. Methods: We performed a retrospective review ...

2016
Akinwumi Komolafe Ahmadu Bello Saad Aliyu Ahmed Mustapha Akanji Ajani Ayodeji Akeem Salami Olutosin Alaba Awolude Abideen Olayiwola Oluwasola

Triple negative epithelial ovarian cancer (TNEOC) refers to Background: ovarian carcinomas that do not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptortype 2 (HER-2/neu). The aim of this study is to determine the pattern of triple negative epithelial ovarian cancer in indigenous African women. : We performed a retrospective review of ER, PR a...

2012
Dai Horiuchi Leonard Kusdra Noelle E. Huskey Sanjay Chandriani Marc E. Lenburg Ana Maria Gonzalez-Angulo Katelyn J. Creasman Alexey V. Bazarov James W. Smyth Sarah E. Davis Paul Yaswen Gordon B. Mills Laura J. Esserman Andrei Goga

Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes, resulting in increased activity of the MYC pathway. In primary breast tumors, MYC signaling did ...

2009
Danica L. Rowe Tuba Ozbay Ruth M. O’Regan Rita Nahta

In the current study, we sought to examine the effects of curcumin in a specific type of breast cancer called triple negative breast cancer. These cancers lack expression of the estrogen and progesterone receptors and do not over-express HER2. Current treatment for triple negative breast cancers is limited to cytotoxic chemotherapy, and upon relapse, there are not any therapies currently availa...

Journal: :Brain pathology 2011
Young-Ho Kim Joel Lachuer Michel Mittelbronn Werner Paulus Benjamin Brokinkel Kathy Keyvani Ulrich Sure Karsten Wrede Sumihito Nobusawa Yoichi Nakazato Yuko Tanaka Anne Vital Luigi Mariani Hiroko Ohgaki

We recently reported that the vast majority (>90%) of low-grade diffuse gliomas (diffuse astrocytoma, oligoastrocytoma and oligodendroglioma) carry at least one of the following genetic alterations: IDH1/2 mutation, TP53 mutation or 1p/19q loss. Only 7% of cases were triple-negative (ie, lacking any of these alterations). In the present study, array comparative genomic hybridization (CGH) in 15...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید